ERBB2 and hepatocellular carcinoma: Although mTOR inhibitors such as everolimus, temsirolimus and deforolimus have been approved for the treatment of RCC (renal cell carcinoma), HER2-negative breast cancer and pancreatic neuroendocrine tumor [23–25], they haven’t obtained approval for treatment in HCC patients.